AU700631B2 - Prothrombin derivatives - Google Patents

Prothrombin derivatives Download PDF

Info

Publication number
AU700631B2
AU700631B2 AU58871/96A AU5887196A AU700631B2 AU 700631 B2 AU700631 B2 AU 700631B2 AU 58871/96 A AU58871/96 A AU 58871/96A AU 5887196 A AU5887196 A AU 5887196A AU 700631 B2 AU700631 B2 AU 700631B2
Authority
AU
Australia
Prior art keywords
thrombin
prothrombin
hirudin
amino acid
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU58871/96A
Other languages
English (en)
Other versions
AU5887196A (en
Inventor
Johann Eibl
Falko-Gunter Falkner
Bernhard Fischer
Artur Mitterer
Uwe Schlokat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Publication of AU5887196A publication Critical patent/AU5887196A/en
Application granted granted Critical
Publication of AU700631B2 publication Critical patent/AU700631B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU58871/96A 1995-06-13 1996-06-12 Prothrombin derivatives Ceased AU700631B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT1006/95 1995-06-13
AT0100695A AT404357B (de) 1995-06-13 1995-06-13 Prothrombin-derivate
PCT/AT1996/000105 WO1996041868A2 (fr) 1995-06-13 1996-06-12 Derives de prothrombine

Publications (2)

Publication Number Publication Date
AU5887196A AU5887196A (en) 1997-01-09
AU700631B2 true AU700631B2 (en) 1999-01-07

Family

ID=3504770

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58871/96A Ceased AU700631B2 (en) 1995-06-13 1996-06-12 Prothrombin derivatives

Country Status (9)

Country Link
US (1) US6086871A (fr)
EP (1) EP0833897A2 (fr)
JP (1) JPH11507542A (fr)
AT (1) AT404357B (fr)
AU (1) AU700631B2 (fr)
CA (1) CA2224634A1 (fr)
CZ (1) CZ402097A3 (fr)
HU (1) HUP9900506A3 (fr)
WO (1) WO1996041868A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452768C (fr) * 2001-07-06 2011-06-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Procede relatif a l'elaboration de thrombine humaine par modification genique
AU2008202376B2 (en) * 2001-07-06 2011-02-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing human thrombin by gene modification technique
US20030099957A1 (en) * 2001-09-28 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
WO2006104398A1 (fr) * 2005-03-26 2006-10-05 Protemix Corporation Limited Compositions antagonistes du cuivre
JPWO2008059917A1 (ja) 2006-11-15 2010-03-04 チッソ株式会社 トロンビン変異体
PL3078743T3 (pl) 2007-09-28 2020-11-02 Portola Pharmaceuticals, Inc. Antidotum dla inhibitorów czynnika XA i sposoby ich stosowania
EP2344174B1 (fr) * 2008-10-27 2016-04-27 Trustees Of Tufts College Acides nucléiques codant des peptides destinés au traitement de blessures, composés antiangiogéniques, et utilisations correspondantes
JP5709316B2 (ja) 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
EP3604510A1 (fr) 2009-03-30 2020-02-05 Portola Pharmaceuticals, Inc. Antidotes pour inhibiteurs du facteur xa et procédés d'utilisation associes
US9056106B2 (en) 2009-07-15 2015-06-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
EP2471945A1 (fr) * 2010-12-30 2012-07-04 Siemens Healthcare Diagnostics Products GmbH Procédé de détermination d'inhibiteurs de coagulation
JP2014515740A (ja) 2011-03-30 2014-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝固薬の解毒剤
CN104470532A (zh) * 2012-04-17 2015-03-25 奥胡斯大学 SorCS1在治疗肥胖症及超重中的应用
GB2504499A (en) * 2012-07-31 2014-02-05 Baxter Healthcare Sa Selective measurement of active human protease coagulation factors
WO2015183085A1 (fr) 2014-05-26 2015-12-03 Academisch Ziekenhuis Leiden Protéines prohémostatiques pour le traitement d'une hémorragie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
CA2000887A1 (fr) * 1988-11-01 1990-05-01 Cecilia S.L. Ku Materiaux thromboresistants et methode de production
ATE119195T1 (de) * 1989-01-25 1995-03-15 Ciba Geigy Ag Monoklonale antikörper, spezifisch für hirudin.
WO1991011519A1 (fr) * 1990-01-26 1991-08-08 Immuno Aktiengesellschaft Facteurs sanguins produits par recombinaison et procede pour l'expression de ces facteurs sanguins, ainsi que virus de la vaccine utilises dans ce procede
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
ATE293168T1 (de) * 1993-11-12 2005-04-15 Gilead Sciences Inc Thrombin mutanten
AT401270B (de) * 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna

Also Published As

Publication number Publication date
US6086871A (en) 2000-07-11
EP0833897A2 (fr) 1998-04-08
JPH11507542A (ja) 1999-07-06
WO1996041868A2 (fr) 1996-12-27
ATA100695A (de) 1998-03-15
HUP9900506A2 (hu) 1999-06-28
CA2224634A1 (fr) 1996-12-27
AU5887196A (en) 1997-01-09
WO1996041868A3 (fr) 1997-04-10
AT404357B (de) 1998-11-25
HUP9900506A3 (en) 2001-10-29
CZ402097A3 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
AU700631B2 (en) Prothrombin derivatives
US7122634B2 (en) Modified factor VIII
EP0728210B1 (fr) Mutants de thrombine
Hovinga et al. Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353--> Pro leading to loss of a kallikrein cleavage site
US7084109B2 (en) FVIIa antagonists
EP0703923B1 (fr) Peptides derives du facteur vii
US6624289B1 (en) Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
Girard et al. Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2
EP1203014B1 (fr) ANTAGONISTE PEPTIDE DU FACTEUR FVIIa
US5876971A (en) Thrombin inhibitor from the saliva of protostomia
JP2001501803A (ja) 改変された活性を有するハイブリッド第▲ｖｉｉｉ▼因子
US7109170B2 (en) Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7425533B2 (en) Modified hirudin proteins and T-cell epitopes in hirudin
KOLKMAN et al. Surface-loop residue Lys316 in blood coagulation Factor IX is a major determinant for Factor X but not antithrombin recognition
RU2122583C1 (ru) Способ получения белка, обладающего опосредованной фактором vii активностью в свертывании крови
US6841534B2 (en) Protein Z-dependent protease inhibitor
US7060484B1 (en) Polypeptides and coagulation therapy
US8088372B2 (en) Thrombin mutant
Monroe et al. Activation of normal and abnormal human factor IX with trypsin
WO2006031226A1 (fr) Region du domaine des proteases du facteur ixa en interaction avec le facteur viiia, et procedes correspondants
Huang Mutational studies of factor X activation by tissue factor-factor VIIa
Lawson Tissue factor dependent hemostasis
Smith The molecular mechanism of factor IX activation by factor XIa
Côté Studies of structure-function relationships in two human coagulation proteins: factor XII and prothrombin
WO1998055130A1 (fr) Analyse hors site d'anticoagulants